Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL.1, 2008, Pages 43-55

  Schwarz, B ^a   Gouveia, M ^b   Chen, J ^c   Nocea, G ^d   Jameson, K ^e   Cook, J ^c   Krishnarajah, G ^f   Alemao, E ^c   Yin, D ^g   Sintonen, H ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CATHOLIC UNIVERSITY OF PORTUGAL   (Portugal)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MSD   (Spain)

^e MSD   (United Kingdom)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cost effectiveness; Diabetes related complications; Discrete event simulation; Economic evaluation; Economic modelling; Sitagliptin; Type 2 diabetes; UKPDS

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PYRAZINE DERIVATIVE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; BIOLOGICAL MODEL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; ECONOMICS; EUROPE; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, ECONOMIC; PYRAZINES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 43449118702     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00886.x     Document Type: Article

References (38)

1. Rathmann W, Haastert B, Icks A et al. The diabetes epidemic in the elderly population in Western Europe: data from population-based studies. Gesundheitswesen 2005; 67 (Suppl. 1): S110-S114.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. International Diabetes Federation. The Diabetes Atlas. IDF, Brussels, 2003. Available from URL: http://www.idf.org. Accessed 2 July 2007.
4. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD. Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health 2004; 14: 3-9.
5. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45: S5-S12.
6. Coffey JT, Brandle M, Zhou H et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25: 2238-2243.
7. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22: 340-349.
8. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
9. Gerich JE. The importance of tight glycemic control. Am J Med 2005; 118: 7S-11S.
10. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287: 2542-2551.
11. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735-744.
12. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005; 28: 337-442.
13. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
15. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
16. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 2004; 4: 589-596.
17. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
18. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741-750.
19. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643.
20. International Diabetes Federation. IDF Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes. IDF, Brussels, 2005. Available from URL: http://www.idf.org. Accessed 2 July 2007.
21. Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab 2008; 10 (Suppl. 1): 33-42.
22. Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47: 1747-1759.
23. University of Oxford Diabetes Trial Unit (DTU) and Health Economics Research Centre (HERC). UKPDS Outcomes Model: User Manual. Version 1.1. Headington, Oxford, UK. Available from URL: http://www.dtu.ox.ac.uk/outcomesmodel. Accessed 1 November 2007.
24. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 43 (CG43): Obesity. London, UK. Available from URL: http://guidance.nice.org.uk/CG43/guidance. Accessed 24 September 2007.
25. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005; 6: 197-202.
26. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliotin when added to ongoing metaformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; [Epub ahead of print].
27. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
28. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
29. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
30. Alvarez Guisasola F, Povedano ST, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management Study. Diabetes Obes Metab 2008; (Suppl. 1): 25-32.
31. Adler AI. Simulating the real world of antihyperglycaemic therapies in type 2 diabetes. Pharmacoeconomics 2006; 24 (Suppl. 1): 1-3.
32. Raikou M, McGuire A, Colhoun HM et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007; 50: 733-740.
33. Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2006; 49: 2634-2641.
34. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007; 30: 1638-1646.
35. Federal Ministry of Health and Women (Bundesministerium fur Gesundheit, Famile und Jugend). Public Health in Austria 2005. Available from URL: http://www.bmgfj.gv.at/cms/site/attachments/8/6/6/CH0083/CMS1051011595227/public_health_in_austria_2005_internet.pdf. Accessed 6 September 2007.
36. Alemao E, Yin D, Sintonen H, Salomaa V, Jousilahti P. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study. Am J Cardiovasc Drugs 2006; 6: 349-355.
37. Scottish Government Health and Community Care. The Scottish Health Survey: 2003 Results. Available from http://www.scotland.gov.uk/Publications/2005/11/25145024/50251. Accessed 6 September 2007.
38. Stevens RJ, Stratton IM, Holman RR. UKPDS58 - modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes. J Diabetes Complications 2002; 16: 371-376.